ChemicalBook > CAS DataBase List > D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID

D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID

CAS No.117414-74-1
Chemical Name:D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID
CBNumber:CB2158312
Molecular Formula:C8H15N2O5P
Formula Weight:250.19
MOL File:117414-74-1.mol

D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Property

Boiling point 555.6±60.0 °C(Predicted)
Density 1.449±0.06 g/cm3(Predicted)
storage temp. Desiccate at RT
form Powder
pka 1.27±0.10(Predicted)
color White
Water Solubility Soluble to 100 mM in water
FDA UNII 7LYU6ZF84G
UNSPSC Code 12352200
NACRES NA.77

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Hazard statements
Precautionary statements

D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Price More Price(1)

Brand: Sigma-Aldrich(India)
Product number: 5.04840
Product name : (R)-CPPene - CAS 117414-74-1 - Calbiochem
Purity:
Packaging: 10MG
Price: ₹32950
Updated: 2022/06/14
Buy: Buy

D-4-[(2E)-3-PHOSPHONO-2-PROPENYL]-2-PIPERAZINECARBOXYLIC ACID Chemical Properties,Usage,Production

Uses D-CPP-ene is a potent, competitive NMDA antagonist (1). NMDA antagonists such as this may increase sucrose intake through hunger satiation delay (2).
Definition ChEBI: Midafotel is a member of the class of piperazines that is piperazine substituted by a carboxy group at position 2R and a (1E)-1-phosphonoprop-1-en-3-yl group at position 4. It is an antagonist of N-methyl-D-aspartate receptors (NMDARs) and was in clinical development by Novartis for the treatment of cognition disorders and brain injuries (now discontinued). It has a role as a NMDA receptor antagonist, a neuroprotective agent and an anticonvulsant. It is a piperazinecarboxylic acid, a monocarboxylic acid, a member of phosphonic acids, an olefinic compound and a tertiary amino compound.
Biological Activity Potent and competitive NMDA antagonist (K i = 40 nM). Centrally active following systemic administration.

in vivo

Midafotel (15 mg/kg; i.p.) causes intense stereotyped behaviors in rats^[2].
Midafotel (1.5, 4.5, 15 mg/kg; i.v.; initiated 15 min prior to MCA occlusion (followed by constant infusion at 1, 3 or 10 mg/kg/h)) produces dose-dependent reductions in the volumes of infarction; the dose of 4.5 mg/kg being the most effective in focal cerebral ischemia in the rat^[3].

Animal Model:	Adult female Wistar rats^[2]
Dosage:	15 mg/kg
Administration:	I.p.
Result:	Induced the typical PCP-like behavioral syndrome with ataxia, hyperlocomotion and stereotyped behaviors, i.e., head weaving, stereotyped sniffing, face washing and grooming, significantly increased extracellular levels of HVA and 5-HIAA in the striatum.

IC 50 NMDA Receptor: 39 nM ()
storage Room temperature